Off-drug weight regain was observed and was accompanied by worsening glycemia and increase in progression to type 2 diabetes. Three-year safety of tirzepatide for weight loss Sean Wharton Sean Wharton, MD, FRCPC, PharmD , medical director of the Wharton Medical Clinic, adjunct professor at McMaster University in Hamilton, Ontario, and York University in Toronto, academic staff at Womens College Hospital and clinical staff at Hamilton Health Sciences, presented the main safety results of the 3-year trial
This dose titration process allows the body to adjust to the medication while establishing which dose provides the optimal balance of effectiveness and tolerability for each patient
These patches are designed to deliver various substances into the bloodstream through the skin to ward off some of the most common symptoms of everyday life
However, some users report better tolerability with tirzepatide, possibly due to the GIP component modulating GLP-1 effects